Benitec Biopharma: OPMD Program Continues To Advance With Catalysts [Seeking Alpha]
Benitec Biopharma Inc. (BNTC)
US:NASDAQ Investor Relations:
benitec.com/for-investors/investor-faqs
Company Research
Source: Seeking Alpha
Play 10min Summary Benitec Biopharma Inc.'s BB-301 showed positive interim results in treating OPMD, allowing for higher dosing in 2025 and a potential late-stage trial in 2026. BB-301 demonstrated significant improvements in swallowing function and reduced pharyngeal residue, with no serious adverse events reported in the phase 1b/2a study. Financially, Benitec Biopharma is well-positioned with $50.9 million in cash, sufficient to fund operations through 2025, thanks to a $40 million PIPE financing. Risks include uncertain efficacy and safety of higher BB-301 doses, and regulatory hurdles for advancing to pivotal phase 3 trials. Looking for more investing ideas like this one? Get them exclusively at Biotech Analysis Central. Learn More » Solskin Benitec Biopharma Inc. NASDAQ: BNTC ) recently reported positive results from its phase 1b/2a clinical study using BB-301 for the treatment of patients with Oculopharyngeal Muscular Dystrophy [OPMD]. It reported these posit
Show less
Read more
Impact Snapshot
Event Time:
BNTC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BNTC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BNTC alerts
High impacting Benitec Biopharma Inc. news events
Weekly update
A roundup of the hottest topics
BNTC
News
- Hedge funds investors own a significant stake of 38% in Benitec Biopharma Inc. (NASDAQ:BNTC) [Yahoo! Finance]Yahoo! Finance
- Benitec Biopharma Inc. (NASDAQ: BNTC) was upgraded by analysts at Baird R W to a "strong-buy" rating.MarketBeat
- Benitec Biopharma Inc. (NASDAQ: BNTC) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $28.00 price target on the stock.MarketBeat
- Benitec Biopharma Inc. (NASDAQ: BNTC) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $28.00 price target on the stock.MarketBeat
- Benitec Biopharma Inc. (NASDAQ: BNTC) is now covered by analysts at Robert W. Baird. They set an "outperform" rating and a $30.00 price target on the stock.MarketBeat
BNTC
Sec Filings
- 12/26/24 - Form 4
- 12/13/24 - Form 8-K
- 12/11/24 - Form 4
- BNTC's page on the SEC website